Arm Holdings plc - American Depositary Shares (ARM)

One is growing revenue above 100% by wiring AI data centers together, while the other collects royalties on nearly every mobile chip. Which one has the stronger case for your portfolio?

Arm and ASML sit at opposite ends of the chip supply chain, but a sharp gap in their valuations may tip the scales for cautious buyers.

Why pay up for the Claude maker's shares when the e-commerce giant already collects from it?

Arm CEO Rene Haas is reportedly under consideration for the Nvidia job.

Nvidia's board has reportedly approached Rene Haas about replacing Jensen Huang. So investors suddenly have to price in the risk of losing the leader behind its data center push.

Anthropic scaled back its IPO valuation target. Should that worry investors?

Jensen Huang has resigned as CEO of Nvidia.

Enrollment is ahead of plan in its pivotal ovarian cancer trial as cash tightens.

Three Dow giants pair market dominance with the financial strength to keep growing for the next decade.

Brookfield's latest results are a big reason I keep adding to my position.

Jensen Huang has resigned as Nvidia CEO. What does it mean for Nvidia stock?

Nvidia just lost its CEO -- so why is Micron stock down?

Investors may be viewing this company's future as being more dependent on the AI industry than it actually is.

Chip stocks broadly rallied on Wednesday as investors went bargain-hunting. The Philadelphia semiconductor index, or SOX, surged.

A regulatory settlement in Ontario will shrink reported revenue by CAD 105 million while barely denting operating profit, exposing the real earnings power underneath.

Both of these companies are spending heavily today to build the next decade's growth.

AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology

Management is betting on branded hardware over third-party OEM work, a shift that could reshape margins for years to come.

The financial company posted an impressive jump in adjusted earnings.

Definium Therapeutics (NASDAQ:DFTX) plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said. The company intends to s

Management details the phase III trial and U.S. approval timeline for its lead asset.

(BPT) - For Simone Duven, using her hands isn't optional. Paralyzed from the waist down, she relies on them to move her wheelchair, transfer in and out of bed and shift her weight to help prevent pressure sores. When pain began shooting through both wrists, even everyday movements were tough.

The AI data analytics stock is now trading 19% below its October high.

Myomo (NYSEAMERICAN:MYO) reported record third-quarter revenue of $12.3 million, up 22% from a year earlier, and narrowed its full-year revenue guidance as referrals and higher sales of its powered arm braces helped improve operating performance. The company reached approximately break-even adjuste